Ginkgo Bioworks (DNA)
(Delayed Data from NYSE)
$0.27 USD
-0.02 (-5.46%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $0.27 0.00 (-0.07%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DNA 0.27 -0.02(-5.46%)
Will DNA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DNA
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
Ginkgo Bioworks Holdings, Inc. (DNA) Advances While Market Declines: Some Information for Investors
DNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
Why the Market Dipped But Ginkgo Bioworks Holdings, Inc. (DNA) Gained Today
Ginkgo Bioworks Holdings, Inc. (DNA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Other News for DNA
Ginkgo Bioworks: From Growth To Value
Ginkgo Bioworks: Underperform Rating Due to Financial Strain and Uncertain Strategic Outcomes
Ginkgo Bioworks Reports Second Quarter 2024 Financial Results
DNA Stock Earnings: Ginkgo Bioworks Holdings Misses EPS, Beats Revenue for Q2 2024
Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2024 Earnings Call Transcript